Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-09
2007-01-09
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S492000, C514S184000, C548S105000, C556S136000
Reexamination Certificate
active
10794035
ABSTRACT:
A series of dynamic platinum compounds for cancer treatment are described. The compounds may become active and inactive reversibly.
REFERENCES:
patent: 4140707 (1979-02-01), Cleare et al.
patent: 4207416 (1980-06-01), Hoeschele
patent: 4228090 (1980-10-01), Hydes et al.
patent: 4760157 (1988-07-01), Child et al.
patent: 4797393 (1989-01-01), Farrell et al.
patent: 4808730 (1989-02-01), Bitha et al.
patent: 4937358 (1990-06-01), Bitha et al.
patent: 4996337 (1991-02-01), Bitha et al.
patent: 5107007 (1992-04-01), Farrell
patent: 5178876 (1993-01-01), Khokhar et al.
patent: 5466678 (1995-11-01), Kawabata et al.
patent: 5529775 (1996-06-01), Mikulski et al.
patent: 5844001 (1998-12-01), McClay et al.
patent: 5922689 (1999-07-01), Shaw
patent: 5958892 (1999-09-01), Mukhopadhyay et al.
patent: 6001817 (1999-12-01), Shaw
patent: 6056973 (2000-05-01), Allen et al.
patent: 6130245 (2000-10-01), Shaw
patent: 6297245 (2001-10-01), Shaw
patent: 6534096 (2003-03-01), Shaw
patent: 6548541 (2003-04-01), Shaw
patent: 9-59288 (1997-03-01), None
patent: WO 88/02261 (1988-04-01), None
US 6,458,832, 10/2002, Shaw (withdrawn)
Colombo et al., 1987, CAS: 106:12460.
Pasini et al., 1986, CAS: 104:60959.
Krylova et al., 2000, CAS: 134:47548.
Berkow, R; Fletcher, A. J., Eds.The Merck Manual of Diagnosis and Therapy, 16thEdition, 1992, p. 1280.
Erickson, L. E.; McDonald, J. W.; Howie, J. K.; Clow, R. P. “Proton Magnetic Resonance Studies of Amino Acid Complexes of Platinum (II). I. Synthesis, Spectral Interpretation, and Conformational Implications”,Journal of the American Chemical Society, 1968, vol. 90, pp. 6371-6373.
Fichtinger-Schepman, A. M. J.; van der Veer, J. L.; den Hartog, J. H. J.; Lohman, P. H. M.; Reedijk, J. “Adducts of the Antitumor Drugcis-Diamminedichloroplatinum(II) with DNA: Formation, Identification, and Quantitation,”Biochemistry, 1985, vol. 24, pp. 707-713.
Abstract of: Giandomenica, C.M.; Abrams, M. J.; Murrer, B. A.; Vollano, J. F.; Barnard, C. F. J.; Harrap, K. R.; Goddard, P. M.; Kelland, L. R.; Morgan, S. E. “Synthesis and Reactions of a New Class of Orally Active Platinum (IV) Antitumor Complexes,”Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, 1991, pp. 93-100.
Gilman, A. G., Ed.Goodman&Gilman's The Pharmacological Basis of Therapeutics, Eighth Edition, 1990, pp. 300-301.
Hollis, L. S.; Amundsen, A. R.; Stern E. W. “Chemical and Biological Properties of a New Series ofcis-Diammineplatinum(II) Antitumor Agents Containing Three Nitrogen Donors:cis-[Pt(NH3)2(N-donor)Cl]+,” Journal of Medicinal Chemistry, 1989, vol. 32, pp. 128-136.
Kuebler, Jr., J. R., Bailar, Jr., J. C. “The Stereoisomerism of Complex Inorganic Compounds. XIV. Studies Upon the Stereochemistry of Saturated Tervalent Nitrogen Compounds”,Journal of the American Chemical Society, 1952, vol. 74, pp. 3535-3538.
Miller, B.; Wild, S.; Zorbas, H.; Beck, W. “Synthesis and Biological Activity ofcis-Dichloro Mono-and Bis(Platinum) Complexes withN-Alkyl- Ethylenediamine Ligands,”Inorganica Chimica Acta, 1999, vol. 290, pp. 237-246.
Miller, S. K.; Marzilli, L. G. “Interaction of Platinum Antitumor Agents with Guanine Nucleosides.195Pt and1H NMR Spectroscopic Characterization of Compound III,”Inorganic Chemistry, 1985, vol. 24, pp. 2421-2425.
Abstract of: Mong, S.; Huang, C. H.; Prestayko, A. W.; Crooke, Stanley T. “Effects of Second-Generation Platinum Analogs on Isolated PM-2 DNA and Their Cytotoxicity in Vitro and In Vivo,”Cancer Research, 1980, vol. 40(9), pp. 3318-3324.
Peresie, H. J.; Kelman, A. D. “Reactions of Platinum(II) Complexes with Guanine Nucleosides and Nucleotides,”Inorganica Chimica Acta, 1978, vol. 29, pp. L247-L248.
Pinkard, F. W.; Sharratt, E.; Wardlaw, W.; Cox, E. G., “Isomerides of Quadricovalent Palladium and Platinum”,Journal of the Chemical Society, 1934, pp. 1012-1016.
Abstract of: Plotnikov, V.M.; Kazakov, S. A.; Merkulov, V. G. “Immunobiological Activity of Platinum (II) Coordination Compounds Complexed with Immunoglobulin Fragments,”Byulleten Eksperimental noi Biologii i Meditsiny, 1989, vol. 108(9), pp. 313-315.
Stewart, D. J.; Dulberg, C. S.; Mikhael, N. Z.; Redmond, M. D.; Montpetit, V. A. J.; Goel, R. “Association of Cisplatin Nephrotoxicity with Patent Characteristics and Cisplatin Administration Methods,”Cancer Chemotherapy and Pharmacology, 1997, vol. 40(4), pp. 293-308 (including EMBASE Abstract).
Taylor D. M.; Tew, K. D.; Jones, J. D., “Effects ofcis-Dichlorodiammine Platinum (II) on DNA Synthesis in Kidney and Other Tissues of Normal Tumour-Bearing Rats,”European Journal of Cancer, 1976, vol. 12(4), pp. 249-254.
Abstract of: Vollano, J. F.; Blatter, E. E.; Dabrowiak, J. C. “DNA Breakage By a Perhydrate Complex of cis-Dichloro-cis-diammine-trans-dihydroxyplatinum (IV) (cis,cis, trans-Pt(IV)C12(NH3)2(OH)2),”Journal of the American Chemical Society, 1984, vol. 106(9), pp. 2732-2733.
Abstract of: Wondrak, E. M.; Loewer, J.; Kurth R. “Inhibition of HIV-1 RNA-dependent DNA Polymerase and Cellular DNA polymerases α, β and γ by Phosphonoformic Acid and Other Drugs,”Journal of Antimicrobial Chemotherapy, 1988, vol. 21(2), pp. 151-161.
Brinks Hofer Gilson & Lione
McKane Joseph K.
Shiao Robert
Unitech Pharmaceuticals, Inc.
LandOfFree
Dynamic anticancer platinum compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dynamic anticancer platinum compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dynamic anticancer platinum compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3768753